Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBT (2021 - 2025)

ARS Pharmaceuticals' EBT history spans 5 years, with the latest figure at -$41.5 million for Q4 2025.

  • For Q4 2025, EBT fell 179.71% year-over-year to -$41.5 million; the TTM value through Dec 2025 reached -$179.4 million, down 10413.1%, while the annual FY2025 figure was -$171.4 million, 2168.28% down from the prior year.
  • EBT for Q4 2025 was -$41.5 million at ARS Pharmaceuticals, up from -$53.2 million in the prior quarter.
  • Across five years, EBT topped out at $52.0 million in Q4 2024 and bottomed at -$53.2 million in Q3 2025.
  • The 5-year median for EBT is -$18.3 million (2023), against an average of -$12.2 million.
  • The largest YoY upside for EBT was 397.08% in 2023 against a maximum downside of 224.76% in 2023.
  • A 5-year view of EBT shows it stood at $46.6 million in 2021, then crashed by 133.12% to -$15.4 million in 2022, then surged by 397.08% to $45.9 million in 2023, then grew by 13.39% to $52.0 million in 2024, then plummeted by 179.71% to -$41.5 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's EBT are -$41.5 million (Q4 2025), -$53.2 million (Q3 2025), and -$47.6 million (Q2 2025).